	Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol Perimbeti S, Jamroze A, Gopalakrishnan D, Jain R, Jiang C, Holleran JL, Parise RA, Bies R, Quinn D, Attwood K, Liu X, Green K, Kirk JS, Beumer JH, Tang DG, Chatta G. PMID: 41315064 [PubMed - indexed for MEDLINE]
	Low-dose abiraterone acetate for the treatment of prostate cancer: An observational cohort study. Farm Hosp Di-Giuseppe LA, Ramirez-Murillo RA, Aymar MD, Basbus LR, Cornec M, Terrasa SA, Posadas-Martínez ML, Burgos MA, Buela G, Cayol F. PMID: 41314925 [PubMed - as supplied by publisher]
	Bladder EpiCheck triggered Photodynamic Diagnosis biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy. Eur Urol Oncol Mariappan P, Hart-Brooke J, Sparks R, Lord-McKenzie T. PMID: 41314886 [PubMed - as supplied by publisher]
	Assessing risk stratification in Bacillus Calmette-GuÃ©rin-treated high-grade Ta nonmuscle-invasive bladder cancer patients. Urol Oncol Finocchiaro A, Contieri R, Piccolini A, Brin P, Moretto S, Dagnino F, Aljoulani M, Uleri A, Avolio P, Beatrici E, Mancon S, Paciotti M, Fasulo V, Saita A, Casale P, Lughezzani G, Buffi N, Lazzeri M, Hurle R. PMID: 41314879 [PubMed - as supplied by publisher]
	Comparison of spinal versus general anaesthesia in high-risk non-muscle invasive bladder cancer: study protocol for a randomised controlled trial. BMJ Open Fang CW, Shau WY, Fan SZ, Chueh JS. PMID: 41314851 [PubMed - indexed for MEDLINE]
	Spatial patterns of testicular cancer diagnosis in Australia, 2010-2019. Spat Spatiotemporal Epidemiol Bainomugisa CK, Dasgupta P, Cameron JK, Tran B, Cramb SM, Baade PD. PMID: 41314725 [PubMed - indexed for MEDLINE]
	Primary endpoint analysis of the phase II DESTINATION-MRL trial for patients with intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys Dassen MG, Tree AC, Wiersema L, Neijndorff B, de Ruiter P, van der Linden J, Mitchell A, Dunlop A, Alexander S, Breitkreutz DY, Cooper S, Janssen T, Pos F, Vesprini D, van der Heide UA. PMID: 41314554 [PubMed - as supplied by publisher]
	Comparison of the therapeutic potential of exosomes derived from different cells for the treatment of prostate cancer. Crit Rev Oncol Hematol Mehr FK, Emtiazi N, Zolfi E, Moradi Y. PMID: 41314483 [PubMed - as supplied by publisher]
	Exploration of oxidative stress-related molecular signature for clear cell renal cell carcinoma. Discov Oncol Jin Z, Hu B, Zhu S, Fu S, Deng Z, Wang C, Liu J, Wang T, Wu Y. PMID: 41313400 [PubMed]
	Comparing [18F]-PSMA-1007, [18F]-choline positron emission tomography, computerized tomography and bone scintigraphy in prostate cancer recurrence. Medicina (B Aires) Bergero MA, Modina P, Arceluz M, Rios L, Costa L, David C, Faccio F. PMID: 41313098 [PubMed - indexed for MEDLINE]
	A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases. Future Oncol Tombal B, Saad F, Gallardo E, Soares A, Loriot Y, McDermott R, Briers E, Lagström M, Coens C, Poncet C, Fournier B, Gillessen S. PMID: 41313045 [PubMed - as supplied by publisher]
	EXPRESS: HCAR2 inhibits prostate cancer invasion and metastasis by regulating cAMP signaling pathway. J Investig Med Li Y, Chen H, Huang R. PMID: 41312963 [PubMed - as supplied by publisher]
	Association of IL-1Î² Gene Polymorphism with Prostate Cancer Severity, Prostate Volume, and PSA Levels: A Case-Control Study. Asian Pac J Cancer Prev Ismael AA, Hussein AM, Saber AA. PMID: 41312941 [PubMed - indexed for MEDLINE]
	Nonâ€‘coding RNAs in epithelialâ€‘mesenchymal transition of renal cell carcinoma (Review). Mol Med Rep Liu Z, Zhou H, Shen J, Qi Y, Gong X, Zhang C. PMID: 41312723 [PubMed - indexed for MEDLINE]
	LLM-BCgrading: Large language model-based Chinese medical long text classification for bladder cancer grade prediction. Digit Health Pan X, Wen L, Li Y, Zhang Y, Lu M. PMID: 41312143 [PubMed]
	Predictive Value of PSA Bounce Phenomenon after Stereotactic Body Radiation Therapy in a Large Population of Prostate Cancer Patients Treated By 1.5â€‰T MR Guided Adaptive Technique. Prostate Romei A, Orsatti C, Allegra AG, Nicosia L, Pastorello E, Ricchetti F, Giaj-Levra N, De-Colle C, Rigo M, Ruggieri R, Alongi F. PMID: 41311355 [PubMed - as supplied by publisher]
	Integrative multi-omics and single-cell transcriptomics reveal ARHGEF12 driving chemoresistance in bladder cancer. Hereditas Zhu K, Zhang Z, Li T, Sun Y, Zhu J, Wu L, Zhang X, Tong H, Qin Z, Wang A, He W. PMID: 41310897 [PubMed - indexed for MEDLINE]
	Micro-ultrasound for prostate cancer. Nat Rev Urol Guer M, Brisbane WG, Cash H, Ghai S, Klotz L, Wilson PFR, Kinnaird A. PMID: 41310306 [PubMed - as supplied by publisher]
	Is radiofrequency ablation of renal cancer metastases a suitable alternative to surgical metastectomy: A systematic review. Ir J Med Sci McNicholas DP, Dexter E, Hampson A, Evans J, Venugopal S. PMID: 41310301 [PubMed - as supplied by publisher]
	Personalized intensification of treatment for hormone-sensitive prostate cancer. Nat Rev Clin Oncol Cilento MA, Butler LM, Emmett L, Sweeney CJ. PMID: 41310272 [PubMed - as supplied by publisher]

Articles 1 - 20 / 174302

Page 1 of 8716



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy